Denosumab

RANKL Inhibitor·Endocrinology - Thyroid & Bone

Osteoporosis (especially if bisphosphonates are contraindicated/failed)

Authority requiredPBSBIOLOGICProlia (60 mg), Xgeva (120 mg - Oncology)60 mg+2

Max Dose

60 mg Q6M

Half-life

26 Days

Hypocalcemia

HIGH RISK

Renal Adj.

NO ADJ; Ca RISK

Rapid Summary

Overview

Highly potent monoclonal antibody against RANK Ligand. Extremely effective at halting bone resorption. Safe to use in severe renal failure (unlike bisphosphonates).

Maximum Dose

Max 60 mg every 6 months (for osteoporosis). Oncology doses (Xgeva) are 120 mg every 4 weeks.

Clinical Focus

Do not delay or stop denosumab without transition planning: Australian warnings highlight multiple vertebral fracture risk after discontinuation or delayed doses.

Bottom Line

Denosumab is a potent anti-resorptive monoclonal antibody for osteoporosis, but discontinuation causes rapid rebound bone loss with vertebral fracture risk, mandating transition to a bisphosphonate.

Formulation & Access

Brand Names

Prolia (60 mg), Xgeva (120 mg - Oncology)

Parenteral

Pre-filled syringe (60 mg/1 mL) for SC injection. Must be refrigerated.

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Osteoporosis (especially if bisphosphonates are contraindicated/failed).

Off-Label

TGA

Prevention of skeletal related events in bone metastases (Xgeva).

Clinical Place

Second-line for osteoporosis, or first-line in severe CKD (eGFR < 35).

Quick reference

Class & Role

RANKL Inhibitor — Highly potent monoclonal antibody against RANK Ligand.

Route / Formulation

Pre-filled syringe (60 mg/1 mL) for SC injection. Must be refrigerated. (Prolia (60 mg), Xgeva (120 mg - Oncology))

Usual Dose & Max

SC 60 mg as a single injection EVERY 6 MONTHS. Must be co-administered with adequate calcium/Vit D supplementation. Max 60 mg every 6 months (for osteoporosis). Oncology doses (Xgeva) are 120 mg every 4 weeks.

Key Indication Doses

Osteoporosis: SC 60 mg as a single injection EVERY 6 MONTHS. Must be co-administered with adequate calcium/Vit D supplementation. Renal Impairment: No dose adjustment required in CKD or dialysis, but extreme vigilance required for hypocalcemia.

Best Uses

Denosumab is a potent anti-resorptive monoclonal antibody for osteoporosis, but discontinuation causes rapid rebound bone loss with vertebral fracture risk, mandating transition to a bisphosphonate.

Avoid / Cautions

Pre-existing hypocalcemia. Unhealed dental/jaw lesions. Pregnancy Category D.

Key Risks

Metabolic: Severe symptomatic hypocalcemia (tetany, QTc prolongation, seizures), particularly in severe renal impairment. Musculoskeletal: Osteonecrosis of the jaw (ONJ), atypical femoral fractures. CRITICAL — Rebound vertebral fractures upon cessation. Immunological: Increased risk of skin infections (cellulitis).

Key Interactions

Immunosuppressants (additive risk of severe infections).

Monitoring

Check U&E and Calcium/Vit D/Magnesium within 1-2 weeks of injection. Correct any deficiency BEFORE giving the injection. Ensure the patient is booked in precisely for their 6-month follow-up injection.

Clinical Pearl

Unlike bisphosphonates, Denosumab does NOT stay in the bone. When it washes out at 6 months, osteoclasts flood back. If you stop Denosumab, you MUST immediately start a bisphosphonate to lock the bone, otherwise the patient will suffer catastrophic spinal fractures within months.

Access

Authority requiredProlia (60 mg), Xgeva (120 mg - Oncology)

Brand: Prolia (60 mg), Xgeva (120 mg - Oncology)
PBS status: Authority required

Denosumab

RANKL Inhibitor·Endocrinology - Thyroid & Bone

Osteoporosis (especially if bisphosphonates are contraindicated/failed)

Authority requiredPBSBIOLOGICProlia (60 mg), Xgeva (120 mg - Oncology)60 mg+2

Max Dose

60 mg Q6M

Half-life

26 Days

Hypocalcemia

HIGH RISK

Renal Adj.

NO ADJ; Ca RISK

Rapid Summary

Overview

Highly potent monoclonal antibody against RANK Ligand. Extremely effective at halting bone resorption. Safe to use in severe renal failure (unlike bisphosphonates).

Maximum Dose

Max 60 mg every 6 months (for osteoporosis). Oncology doses (Xgeva) are 120 mg every 4 weeks.

Clinical Focus

Do not delay or stop denosumab without transition planning: Australian warnings highlight multiple vertebral fracture risk after discontinuation or delayed doses.

Bottom Line

Denosumab is a potent anti-resorptive monoclonal antibody for osteoporosis, but discontinuation causes rapid rebound bone loss with vertebral fracture risk, mandating transition to a bisphosphonate.

Formulation & Access

Brand Names

Prolia (60 mg), Xgeva (120 mg - Oncology)

Parenteral

Pre-filled syringe (60 mg/1 mL) for SC injection. Must be refrigerated.

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Osteoporosis (especially if bisphosphonates are contraindicated/failed).

Off-Label

TGA

Prevention of skeletal related events in bone metastases (Xgeva).

Clinical Place

Second-line for osteoporosis, or first-line in severe CKD (eGFR < 35).

Quick reference

Class & Role

RANKL Inhibitor — Highly potent monoclonal antibody against RANK Ligand.

Route / Formulation

Pre-filled syringe (60 mg/1 mL) for SC injection. Must be refrigerated. (Prolia (60 mg), Xgeva (120 mg - Oncology))

Usual Dose & Max

Key Indication Doses

Best Uses

Denosumab is a potent anti-resorptive monoclonal antibody for osteoporosis, but discontinuation causes rapid rebound bone loss with vertebral fracture risk, mandating transition to a bisphosphonate.

Avoid / Cautions

Pre-existing hypocalcemia. Unhealed dental/jaw lesions. Pregnancy Category D.

Key Risks

Key Interactions

Immunosuppressants (additive risk of severe infections).

Monitoring

Clinical Pearl

Access

Authority requiredProlia (60 mg), Xgeva (120 mg - Oncology)

Brand: Prolia (60 mg), Xgeva (120 mg - Oncology)
PBS status: Authority required